In contrast, TIGIT is overexpressed on CD8+ tumor-infiltrating lymphocytes (TILs) and tumor antigen-specific CD8+ T cells from melanoma patients and often coexpressed with the inhibitory receptor PD-1 (66). Here, CD8A is linked to neoplasm.